Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo 4-weeks Clear all
Completed Phase 2 Interventional Results available

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

NCT00724048
View directory record Official record
Conditions
Huntington Disease
Interventions
ACR16, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

NCT00894543
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

NCT01250990
View directory record Official record
Conditions
Dyslipidemias
Interventions
Niacin, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

NCT02513550
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

NCT00000774
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Days
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 25, 2026, 11:02 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

NCT07246850
View directory record Official record
Conditions
Sore-throat, Common Cold
Interventions
Beekeeper's Propolis Throat Spray, Placebo Throat Spray
Dietary Supplement
Lead sponsor
Beekeeper's Naturals Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional

Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial

NCT04944836
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Clomiphene Citrate, Rotator Cuff Repair
Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a

NCT02646371
View directory record Official record
Conditions
Shigellosis
Interventions
Flexyn2a, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389
View directory record Official record
Conditions
Depression, Depression, Postpartum
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 25, 2026, 11:02 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

NCT01235559
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
Costa Mesa, California • Escondido, California • Granada Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

NCT05198310
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
KPL-404, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Apple Valley, California • Covina, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Rifaximin in Minimal Hepatic Encephalopathy

NCT00533910
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, placebo
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT05185089
View directory record Official record
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

NCT00656890
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
sterile saline for injection, MDX-1100
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

NCT03726879
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 25, 2026, 11:02 PM EDT
Withdrawn Phase 2 Interventional

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

NCT02252978
View directory record Official record
Conditions
Prostate Cancer
Interventions
ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 25, 2026, 11:02 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

NCT03559517
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 25, 2026, 11:02 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

NCT02982915
View directory record Official record
Conditions
Aging Frailty
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 25, 2026, 11:02 PM EDT